Voyager Therapeutics (NASDAQ:VYGR) Earns Sell (D) Rating from Weiss Ratings

Key Points

• Voyager Therapeutics has received a "sell (D)" rating from Weiss Ratings, while HC Wainwright maintains a "buy" rating with a price target of $30.00.
• Shares of Voyager Therapeutics traded up 11.6% to $5.28, with a 12-month range of $2.64 to $8.27, leading to a total of 1,662,251 shares traded on the day.
• The company's latest quarterly earnings showed a loss of ($0.57) EPS, missing consensus estimates by ($0.09) and reflecting a revenue of $5.20 million against an expected $9.50 million.

Voyager Therapeutics (NASDAQ:VYGR - Get Free Report)'s stock had its "sell (d)" rating restated by analysts at Weiss Ratings in a research note issued to investors on Wednesday,Weiss Ratings reports.

Several other brokerages have also issued reports on VYGR. HC Wainwright restated a "buy" rating and set a $30.00 price target on shares of Voyager Therapeutics in a research note on Monday, September 15th. Wedbush dropped their target price on shares of Voyager Therapeutics from $9.00 to $8.00 and set an "outperform" rating for the company in a research report on Thursday, August 7th. One equities research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $13.25.

Voyager Therapeutics Trading Up 11.6%

NASDAQ VYGR traded up $0.55 during trading on Wednesday, hitting $5.28. 1,662,251 shares of the company traded hands, compared to its average volume of 571,666. The business has a fifty day simple moving average of $3.87 and a 200 day simple moving average of $3.47. The company has a market capitalization of $292.88 million, a P/E ratio of -2.85 and a beta of 0.95. Voyager Therapeutics has a 12 month low of $2.64 and a 12 month high of $8.27.

Voyager Therapeutics (NASDAQ:VYGR - Get Free Report) last posted its quarterly earnings data on Wednesday, August 6th. The company reported ($0.57) EPS for the quarter, missing analysts' consensus estimates of ($0.48) by ($0.09). Voyager Therapeutics had a negative return on equity of 37.65% and a negative net margin of 253.49%.The business had revenue of $5.20 million during the quarter, compared to the consensus estimate of $9.50 million. Equities research analysts predict that Voyager Therapeutics will post -0.91 EPS for the current fiscal year.

Insider Buying and Selling at Voyager Therapeutics

In other news, CFO Nathan D. Jorgensen sold 7,666 shares of the firm's stock in a transaction dated Friday, October 3rd. The stock was sold at an average price of $4.78, for a total value of $36,643.48. Following the completion of the transaction, the chief financial officer owned 123,834 shares in the company, valued at $591,926.52. This trade represents a 5.83% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 4.53% of the stock is owned by insiders.

Hedge Funds Weigh In On Voyager Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of VYGR. Allspring Global Investments Holdings LLC grew its holdings in Voyager Therapeutics by 53.8% during the first quarter. Allspring Global Investments Holdings LLC now owns 60,462 shares of the company's stock worth $204,000 after purchasing an additional 21,149 shares during the period. CWM LLC grew its holdings in Voyager Therapeutics by 856.3% during the first quarter. CWM LLC now owns 10,471 shares of the company's stock worth $35,000 after purchasing an additional 9,376 shares during the period. Privium Fund Management B.V. bought a new position in Voyager Therapeutics during the first quarter worth about $73,000. Invesco Ltd. grew its holdings in Voyager Therapeutics by 100.8% during the first quarter. Invesco Ltd. now owns 48,540 shares of the company's stock worth $164,000 after purchasing an additional 24,368 shares during the period. Finally, Nuveen LLC bought a new position in Voyager Therapeutics during the first quarter worth about $368,000. Institutional investors own 48.03% of the company's stock.

Voyager Therapeutics Company Profile

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.